About Definium Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://definiumtx.com/
Frequently Asked Questions
What is the 52-week range for DFTX?
The 52-week high is $49.7 and the 52-week low is $10.465.
What is the P/E ratio for DFTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for DFTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -85.23%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.04.
Analyst Recommendation Trends
Wall Street analyst consensus for DFTX over the last few months:
Latest DFTX News
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, September 28, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of Septembe
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, with longer-term open
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Psychedelic Sector Optimi Health Plans to Initiate Phase 3 Clinical Trial Evaluating MDMA Therapy for Individuals with PTSD Eli Lilly Completed $2.8 Billion Acquisition of AtaiBeckley, Expanding its Mental Health Pipeline Definium’s Phase 3 Panorama Trial Delivered Positive Results for DT120 in Generalized Anxiety Disorder Psyence BioMed Established Texas Entity to Advance U.S. […]
Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching
Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on […]
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivo
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results
Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets. Is the current share price still grounded in what the business is worth on its books, or has sentiment pulled it away from its underlying equity value? Over the past three years, Definium Therapeutics has delivered a return of roughly 8.9x, which raises the stakes for whether the stock price still lines up with the value recorded on...
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics plans to submit an NDA for DT120 in GAD In the first half of 2027.
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result
Definium Therapeutics recently reported that its Phase 3 Panorama trial of DT120, an LSD-based orally disintegrating tablet, in adults with generalized anxiety disorder met the primary and all key secondary endpoints, with a single 100 µg dose delivering a statistically significant 5.1‑point placebo‑adjusted reduction in HAM‑A anxiety scores at Week 12. The data also showed early and durable symptom relief from just one treatment, with meaningful improvements as soon as Day 2 and no new...
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
Definium Therapeutics (DFTX) After Its Phase 3 Win Still Looks Undervalued
Definium Therapeutics (DFTX) just reported that its second Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met primary and key secondary endpoints, with clinically meaningful, placebo adjusted improvements in anxiety measures. Definium Therapeutics shares have rallied strongly, with a 90 day share price return of 66.6% and a year to date share price gain of 195.09%. The 1 year total shareholder return of 321.47% signals powerful momentum that the latest Phase 3 success...
The Psychedelics News That Sent Definium, Already Up 190% This Year, Soaring
Definium Therapeutics' LSD eased the symptoms of anxiety, the company said Monday as shares took off again.
Psychedelics Are Wall Street’s Next Trip. Why This Biotech Stock Is Already Up 200%.
Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St
DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug
The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder September 14, 2026...
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder - Slideshow
2026-09-14. The following slide deck was published by Definium Therapeutics, Inc.
Definium Therapeutics Shares Rise 20% After Phase 3 Anxiety Trial Meets Primary Endpoint
Definium Therapeutics, Inc. (NASDAQ:DFTX) shares rose 20% after the company reported topline results from its Phase 3 Panorama study evaluating DT120 ODT in patients with generalized anxiety disorder.
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'
Definium Therapeutics announced positive Phase 3 Panorama trial results for DT120 in generalized anxiety disorder patients.
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
NEW YORK, September 14, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s thi
HC Wainwright & Co. Reiterates Buy on Definium Therapeutics, Maintains $70 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $70 price target.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)
Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target
Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.
Definium Therapeutics Reports Topline Results From Panorama, Second Phase 3 Study Of DT120 ODT In Adults With Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints
Study met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3 trial for DT120 ODT in GAD and the third positive Phase 3 trial for DT120 ODTParticipants receiving DT120 ODT 100 µg
DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug
Investors are awaiting topline results from Panorama, its second Phase 3 trial of DT120 in generalized anxiety disorder, set to be unveiled on Monday.
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
NEW YORK, September 13, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiet
Billionaire Stanley Druckenmiller’s 2 New Healthcare Stock Picks
Stanley Druckenmiller’s Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are the notable ones in the healthcare space. Duquesne bought 203,618 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) worth $22.6 million. The fund also […]
RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target
RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
NEW YORK, September 10, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced six poster presentations at the Psych Congress taking place September 15 through 19 in New Orleans, LA.
Definium To Highlight Phase 3 Data And New Research On Anxiety, Depression At Psych Congress
Emerge Phase 3 study podium poster to be featured in "Latest Discoveries & Emerging Trends in MDD" sessionNew epidemiological research on risks associated with anxiety and depression plus five posters across
'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg
https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-permanent-roles
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
NEW YORK, September 08, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for DT120 (lysergide) ODT. The designation was supported by the significant unmet medical need in MDD and results from the Compa
Definium Therapeutics Receives FDA Breakthrough Therapy Designation For DT120 ODT; Second Breakthrough Therapy Designation For DT120 Reinforces Its Potential Across MDD And Generalized Anxiety Disorder
The designation was supported by the significant unmet medical need in MDD and results from the Company's Phase 3 Emerge study, in which a single 100 µg dose of DT120 ODT demonstrated a statistically significant
Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript
Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders September 1, 2026 1:00 PM...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-25 | Karlin Daniel | -10,853 | $36.57 | $396,894 |
| 2026-09-25 | Barrow Robert | -31,550 | $36.57 | $1,153,784 |
| 2026-09-25 | Wiley Matthew T. | -3,097 | $36.57 | $113,257 |
| 2026-09-25 | Roberts Brandi | -3,377 | $36.57 | $123,497 |
| 2026-09-25 | Sullivan Mark | -14,051 | $36.57 | $513,845 |
| 2026-09-18 | Krebs Andreas | -1,629 | - | - |
| 2026-09-18 | Krebs Andreas | +1,629 | $35.52 | $57,862 |
| 2026-09-18 | Vallone Carol A | -1,086 | - | - |
| 2026-09-18 | Vallone Carol A | +1,086 | $35.52 | $38,575 |
| 2026-09-14 | Karlin Daniel | +200,000 | - | - |
| 2026-09-14 | Barrow Robert | +750,000 | - | - |
| 2026-09-14 | Wiley Matthew T. | +125,000 | - | - |
| 2026-09-14 | Roberts Brandi | +125,000 | - | - |
| 2026-09-14 | Sullivan Mark | +125,000 | - | - |
| 2026-09-03 | Barrow Robert | -19,023 | $37.94 | $721,733 |
| 2026-09-02 | Barrow Robert | +40,000 | - | - |
| 2026-08-12 | Barrow Robert | +375,000 | - | - |
| 2026-08-12 | Karlin Daniel | +100,000 | - | - |
| 2026-08-12 | Wiley Matthew T. | +62,500 | - | - |
| 2026-08-12 | Roberts Brandi | +62,500 | - | - |
| 2026-08-12 | Sullivan Mark | +62,500 | - | - |
| 2026-06-25 | Karlin Daniel | -10,035 | $45.03 | $451,876 |
| 2026-06-25 | Barrow Robert | -29,208 | $45.03 | $1,315,236 |
| 2026-06-25 | Wiley Matthew T. | -2,867 | $45.03 | $129,101 |
| 2026-06-25 | Roberts Brandi | -3,013 | $45.03 | $135,675 |
| 2026-06-25 | Sullivan Mark | -13,008 | $45.03 | $585,750 |
| 2026-06-22 | Barrow Robert | +375,000 | - | - |
| 2026-06-22 | Karlin Daniel | +100,000 | - | - |
| 2026-06-22 | Wiley Matthew T. | +62,500 | - | - |
| 2026-06-22 | Roberts Brandi | +62,500 | - | - |
| 2026-06-22 | Sullivan Mark | +62,500 | - | - |
| 2026-06-11 | Adsett Roger | +14,620 | - | - |
| 2026-06-11 | Adsett Roger | +3,555 | - | - |
| 2026-06-11 | CRYSTAL ROGER | +19,188 | - | - |
| 2026-06-11 | CRYSTAL ROGER | +4,666 | - | - |
| 2026-06-11 | Bruhn Suzanne Louise | +19,188 | - | - |
| 2026-06-11 | Bruhn Suzanne Louise | +4,666 | - | - |
| 2026-06-11 | Krebs Andreas | +19,188 | - | - |
| 2026-06-11 | Krebs Andreas | +4,666 | - | - |
| 2026-06-11 | Vallone Carol A | +19,188 | - | - |
| 2026-06-11 | Vallone Carol A | +4,666 | - | - |
| 2026-06-11 | GRYSKA DAVID W | +19,188 | - | - |
| 2026-06-11 | GRYSKA DAVID W | +4,666 | - | - |
| 2026-03-25 | Karlin Daniel | -8,018 | $18.47 | $148,092 |
| 2026-03-25 | Barrow Robert | -24,431 | $18.47 | $451,241 |
| 2026-03-25 | Sullivan Mark | -10,702 | $18.47 | $197,666 |